177 related articles for article (PubMed ID: 10335269)
1. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation.
Desbène S; Van HD; Michel S; Koch M; Tillequin F; Fournier G; Farjaudon N; Monneret C
Anticancer Drug Des; 1998 Dec; 13(8):955-68. PubMed ID: 10335269
[TBL] [Abstract][Full Text] [Related]
2. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
3. Prodrugs of anthracycline antibiotics suited for tumor-specific activation.
Azoulay M; Florent JC; Monneret C; Gesson JP; Jacquesy JC; Tillequin F; Koch M; Bosslet K; Czech J; Hoffman D
Anticancer Drug Des; 1995 Sep; 10(6):441-50. PubMed ID: 7575986
[TBL] [Abstract][Full Text] [Related]
4. Intensely cytotoxic anthracycline prodrugs: glucuronides.
Bakina E; Wu Z; Rosenblum M; Farquhar D
J Med Chem; 1997 Dec; 40(25):4013-8. PubMed ID: 9406592
[TBL] [Abstract][Full Text] [Related]
5. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
7. Prodrug activation gated by a molecular "OR" logic trigger.
Amir RJ; Popkov M; Lerner RA; Barbas CF; Shabat D
Angew Chem Int Ed Engl; 2005 Jul; 44(28):4378-81. PubMed ID: 15942963
[No Abstract] [Full Text] [Related]
8. A doxorubicin prodrug activated by the staudinger reaction.
van Brakel R; Vulders RC; Bokdam RJ; Grüll H; Robillard MS
Bioconjug Chem; 2008 Mar; 19(3):714-8. PubMed ID: 18271515
[TBL] [Abstract][Full Text] [Related]
9. Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.
Desbene S; Van HD; Michel S; Tillequin F; Koch M; Schmidt F; Florent JC; Monneret C; Straub R; Czech J; Gerken M; Bosslet K
Anticancer Drug Des; 1999 Apr; 14(2):93-106. PubMed ID: 10405636
[TBL] [Abstract][Full Text] [Related]
10. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
[TBL] [Abstract][Full Text] [Related]
11. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
Trouet A; Passioukov A; Van derpoorten K; Fernandez AM; Abarca-Quinones J; Baurain R; Lobl TJ; Oliyai C; Shochat D; Dubois V
Cancer Res; 2001 Apr; 61(7):2843-6. PubMed ID: 11306455
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
[TBL] [Abstract][Full Text] [Related]
13. Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapy.
Sinha SC; Li LS; Watanabe S; Kaltgrad E; Tanaka F; Rader C; Lerner RA; Barbas CF
Chemistry; 2004 Oct; 10(21):5467-72. PubMed ID: 15378729
[TBL] [Abstract][Full Text] [Related]
14. Poly (ethylene glycol) prodrug for anthracyclines via N-Mannich base linker: design, synthesis and biological evaluation.
Zhao YJ; Wei W; Su ZG; Ma GH
Int J Pharm; 2009 Sep; 379(1):90-9. PubMed ID: 19540322
[TBL] [Abstract][Full Text] [Related]
15. Self-immolative anthracycline prodrugs for suicide gene therapy.
Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
[TBL] [Abstract][Full Text] [Related]
16. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
17. Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy.
Heine D; Müller R; Brüsselbach S
Gene Ther; 2001 Jul; 8(13):1005-10. PubMed ID: 11438835
[TBL] [Abstract][Full Text] [Related]
18. Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins.
Tietze LF; Major F; Schuberth I; Spiegl DA; Krewer B; Maksimenka K; Bringmann G; Magull J
Chemistry; 2007; 13(16):4396-409. PubMed ID: 17455190
[TBL] [Abstract][Full Text] [Related]
19. Effect of gamma irradiation on spleen cell function and cytotoxicity of doxorubicin.
Lee JW; Sung NY; Kim JK; Kim JH; Raghavendran HR; Yoo YC; Shin MH; Byun MW
Chem Biol Interact; 2008 Jun; 173(3):205-14. PubMed ID: 18486936
[TBL] [Abstract][Full Text] [Related]
20. Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity.
Zhang A; Yao L; An M
Chem Commun (Camb); 2017 Nov; 53(95):12826-12829. PubMed ID: 29143021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
